Clinical study of Miao medicine Qijiao Shengbai Capsule in the prevention and treatment of chemotherapy-induced leukopenia in breast cancer
Objective To observe the clinical efficacy of Qijiao Shengbai Capsule in the prevention and treatment of chemotherapy-induced leukopenia in breast cancer.Methods A multi-center,randomized,and positive drug-controlled clinical trial design was used,enrolling 119 patients with breast cancer undergoing chemotherapy who presented with qi and blood deficiency pattern from four centers.They were randomly assigned to the Qijiao Shengbai Capsule treatment group(n=79)and the Anduolin Capsule control group(n=40)in a ratio of 2:1.The treatment course lasted for 20 days.White blood cell count(WBC),absolute neutrophil count(ANC),and their respective reduction grades,as well as the Chinese medicine(CM)pattern and symptom scores,were compared between the two groups before and after treatment.Additionally,the rates of timely follow-up chemotherapy and medication safety were compared between the two groups.Results After treatment,the CM pattern and symptom scores in both groups decreased compared to those before treatment(P＜0.05).There were no statistically significant differences in WBC,ANC,their respective reduction grades,or the rates of timely follow-up chemotherapy between the two groups(P＞0.05).One patient in the treatment group experienced mild diarrhea,which improved after discontinuing the medication.Conclusion Qijiao Shengbai Capsule has certain advantages in preventing and treating chemotherapy-induced leukopenia in breast cancer patients.It can effectively alleviate the symptoms of qi and blood deficiency and ensure the timely continuation of chemotherapy,with good clinical safety.
breast cancerchemotherapyQijiao Shengbai Capsuleleukopeniaclinical study
万方数据
维普
